Evidence map›Paper›PMID 41057788›Full record

ArticleBMC nephrology2025

Dupilumab-associated anti-glomerular basement membrane nephritis in a patient with eosinophilic granulomatosis with polyangiitis: a case report.

Kei Nakada, Reika Flora Moriya, Kenichi Tanaka, Hiroki Ejiri, Fumiya Kitaguchi, Naoya Suto, Guy Watanabe, Hiroshi Kimura, Mizuko Tanaka, Junichiro James Kazama

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kei NakadaDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikariga-oka, Fukushima, 960-1295, Japan.
Reika Flora MoriyaDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikariga-oka, Fukushima, 960-1295, Japan.
Kenichi TanakaDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikariga-oka, Fukushima, 960-1295, Japan. kennichi@fmu.ac.jp.
Hiroki EjiriDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikariga-oka, Fukushima, 960-1295, Japan.
Fumiya KitaguchiDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikariga-oka, Fukushima, 960-1295, Japan.
Naoya SutoDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikariga-oka, Fukushima, 960-1295, Japan.
Guy WatanabeDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikariga-oka, Fukushima, 960-1295, Japan.
Hiroshi KimuraDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikariga-oka, Fukushima, 960-1295, Japan.
Mizuko TanakaDepartment of Pathology, Jusendo General Hospital, Koriyama, Japan.
Junichiro James KazamaDepartment of Nephrology and Hypertension, Fukushima Medical University, 1, Hikariga-oka, Fukushima, 960-1295, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDupilumab, a human monoclonal immunoglobulin G (IgG) antibody that targets the IL-4 and IL-13 receptors, is used to treat various allergic diseases. Several cases of dupilumab-associated autoimmune diseases have been reported in recent years, however, there have been no reports of anti-glomerular basement membrane (GBM) nephritis. CASE PRESENTATION: A 54-year-old woman had been receiving treatment for eosinophilic granulomatosis with polyangiitis (EGPA) since the age of 31. At the age of 51, due to worsening asthma symptoms and eosinophilic sinusitis, treatment with dupilumab was initiated. She was later admitted to the hospital with fever and rapidly progressive kidney dysfunction. Glucocorticoid therapy was started because the possibility of recurrence of EGPA was considered. However, her kidney dysfunction progressed without response, and she was transferred to our hospital. Laboratory tests on admission showed positive anti-GBM antibodies, and a kidney biopsy showed crescentic glomerulonephritis with linear IgG deposition along the GBM without findings suggesting the recurrence of EGPA, including eosinophilic infiltration, granuloma formation, or necrotizing vasculitis. Based on her laboratory data and kidney pathological findings, anti-GBM nephritis was diagnosed. Plasma exchange was performed a total of seven times. Although the anti-GBM antibody titer was decreased after the plasma exchanges, kidney function did not improve well. After additional treatment with intravenous cyclophosphamide, her kidney function improved, and she was discharged home.

conclusionAnti-GBM nephritis associated with EGPA is extremely rare, and dupilumab may have contributed to its development. In patients receiving dupilumab who develop rapidly progressive kidney dysfunction, the possibility of anti-GBM nephritis should be considered, and prompt diagnosis and therapeutic intervention are essential.

Indexed as

Antibodies, Monoclonal, HumanizedAnti-Glomerular Basement Membrane DiseaseChurg-Strauss SyndromeGranulomatosis with PolyangiitisFemaleHumansMiddle AgedAntibodies, Monoclonal, HumanizeddupilumabAnti-glomerular basement membrane nephritisCase reportDupilumabEosinophilic granulomatosis with polyangiitisRapidly progressive glomerulonephritis

Identifiers

PMID41057788
PMCPMC12506315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.